v3.26.1
Discontinued Operations (Tables)
 6 Months Ended
Jun. 30, 2026
Restructuring Cost and Reserve [Line Items]  
Schedule of Constituting Loss from Discontinued Operations

The major classes of line items constituting loss from discontinued operations are as follows:

 

                     
   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2026   2025   2026   2025 
Revenue  $-   $-   $-   $- 
Cost of revenue   -    -    -    - 
Selling, general and administrative expenses   -    411,153    -    1,408,305 
Research and development expenses   -    127,807    -    393,470 
Impairment loss   -    -    -    14,645,069 
Depreciation and amortization   -    -    -    - 
Interest expense   -    2,287    -    5,718 
Loss on discontinued operations  $-   $541,247   $-   $16,452,562 
NAYA Therapeutics [Member]  
Restructuring Cost and Reserve [Line Items]  
Schedule of Allocation of Purchase Price

In the second quarter of 2025, the Company recognized a loss of $1,534,517 upon the disposition of the 80.1% ownership of NTI.

  

      
Consideration received:     
Series C-1 Preferred  $2,466,810 
NTI Note Receivable   4,803,175 
NTI Series A Preferred   3,879,611 
Business acquisition cost  $11,149,596 
      
Assets and liabilities divested:     
Cash  $6,569 
Other current assets   16,700 
Tradename   257,000 
In process R&D   14,571,000 
Goodwill   3,011,638 
AP & accrued liabilities   (4,804,016)
Debt   (374,778)
Net assets  $12,684,113 
      
Loss on disposition  $1,534,517